Bank Julius Baer & Co
BDTX icon

Bank Julius Baer & Co’s Black Diamond Therapeutics BDTX Stock Holding History

Bank Julius Baer & Co’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30,000
Closed -$254K – 834
2021
Q3 		$254K Sell
30,000
-30,459
-50% -$301K ﹤0.01% 522
2021
Q2 		$737K Buy
60,459
+25,459
+73% +$503K ﹤0.01% 394
2021
Q1 		$849K Buy
+35,000
New +$944K 0.01% 357

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Julius Baer & Co's BDTX Position: Q4 2021 in Review

Bank Julius Baer & Co sold out of Black Diamond Therapeutics (BDTX) in Q4 2021, closing a stake of 30,000 shares — an estimated $254K sold.

Bank Julius Baer & Co first reported a position in BDTX in Q1 2021 and held it in 3 quarters. The position peaked at $849K in Q1 2021. 95 funds tracked by Wall St. Rank hold BDTX as of Q4 2021.

  • Bank Julius Baer & Co reported no remaining Black Diamond Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 30,000 Black Diamond Therapeutics shares in Q4 2021, an estimated $254K.
  • Bank Julius Baer & Co first reported a position in Black Diamond Therapeutics in Q1 2021 and held it in 3 quarters.
  • Bank Julius Baer & Co's Black Diamond Therapeutics position peaked at $849K in Q1 2021.
  • 95 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2021.

Based on Bank Julius Baer & Co's 13F filing for Q4 2021, filed 15 Feb 2022.